Capsulution Expands its Developmental Facilities
New projects on anti-cancer substances
In July, Capsulution started to expand its laboratory facilities and thus adapt to the growing customer demand. The aim is to develop Nanotechnology-based delivery systems for cytotoxic substances, like they are employed in modern cancer therapy. Such active compounds require both special laboratory and occupational health and safety conditions. Therefore, a high development quality and safety standard will be secured by a new, separate working area at Capsulution.
"The extension of the laboratory technology is a vital key to success for our customers and staff alike and at the same time motivates us to further our product development more effectively under the most modern conditions," states Lutz Kröhne, project director at Capsulution. The handling of highly effective new active components (NCEs) will soon be possible too with the help of our new laboratory technology.
Most read news
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.